Cognitive profiles for early diagnosis of Dementia with Lewy bodies (DLB) have been outlined in a new study, out today in ...
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...
Anavex Life Sciences' Blarcamesine trial raises concerns over approval. Learn why AVXL stock is undervalued, reflecting the ...
While many people take supplements for brain health, the research supporting supplemental nutrients' effects on brain health ...
All 16 of Indiana’s designated senior care organizations are now required to have a dementia outreach specialist. The goal is ...
ProMIS Neurosciences (PMN) announced the initiation of its Phase 1b clinical trial evaluating its lead therapeutic candidate, PMN310, in ...
ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b ...
Alzheimer’s drugs could unlock a $13 billion market by 2030, with Biogen, Eli Lilly, Novo Nordisk, Roche, and UCB leading the ...